摘要
目的:研究红景天苷对Aβ1～40海马内注射所致阿尔茨海默病(Alzheimer's disease,AD)模型大鼠的治疗作用并探讨其可能的影响机制。方法:Aβ1～40海马内注射制备AD大鼠模型,术后用不同剂量红景天苷(25,50,75 mg.kg-1)灌胃治疗,每日1次,共21 d。建模成功后,经Morris水迷宫评测大鼠学习记忆能力,并分别测定大鼠海马组织超氧化物歧化酶(SOD)活性、丙二醛(MDA)含量和诱导型一氧化氮合酶(iNOS)、核转录因子κB(NF-κB)及糖基化终末产物受体(RAGE)蛋白表达。结果:AD大鼠在定位航行试验中逃避潜伏期延长,单位时间内跨越原平台次数减少,学习记忆力受损,海马组织SOD活性明显降低,MDA含量明显增高,NF-κB,iNOS及RAGE蛋白表达明显上调。红景天苷50,75 mg.kg-1组大鼠的学习记忆受损得到显著改善(P<0.01)。与模型组相比,红景天苷50 mg.kg-1组SOD活性上调,MDA含量降低,NF-κB,iNOS及RAGE的表达均得到有效抑制(P<0.01)。结论:红景天苷可能通过综合抗氧化应激效应起到治疗阿尔茨海默病的作用。
Objective： To study the effect and possible impact mechanism of salidroside on cognitive ability of Alzheimer＇s disease （AD） model rats induced by amyloid beta peptide （Aβ1-40）. Method： Aβ1.40 was injected into bilateral hippocampus to create the AD model. Afterwards, different doses of salidroside （25,50,75 mg · kg^-1 ） were orally administered for 21 days. Rats＇ learning and memory abilities were detected by Morris water maze testing system. The levels of the superoxide dismutase （SOD） , malondialdehyde （ MDA）, and the expression of nuclear factor-KB （ NF-KB）, inducible nitric oxide synthase （iNOS） and receptor for advanced glycation end products （RAGE） protein in hippocampus were also detected by different methods. Result： The place navigation test showed longer escape latency, low frequency of platform quadrant crossing per unit time, damage in learning capacity, significant decrease in SOD acivity in hippocampus, notable increase in MDA content, NF-KB, iNOS and RAGE protein expressions in rats. Salidroside （50, 75 mg · kg^- 1 ） significantly alleviated the impairments of learning and memory ability. The activity of SOD increased in salidroside （50 mg · kg^-1 ） group. On the contrary, the content of MDA and the expression of NF-KB, iNOS, RAGE significantly decreased in salidroside group compared with that of the Alzheimer＇s disease group （P 〈 0. 01 ）. Conclusion： Salidroside may treat Alzheimer＇s disease by inhibiting the oxidative stress.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2012年第14期2122-2126,共5页
China Journal of Chinese Materia Medica
基金
河北省自然科学基金项目(C2010001471)
